---
type: "Symbol"
title: "Weigao Blood Purification (603014.SH) — Community Discussions"
description: "Community discussions about this stock, including analyst opinions, earnings analysis, and investment strategies from verified financial professionals and active investors."
locale: "en"
url: "https://longbridge.com/en/quote/603014.SH/topics.md"
symbol: "603014.SH"
parent: "https://longbridge.com/en/quote/603014.SH.md"
count: 1
datetime: "2026-03-05T21:50:52.563Z"
locales:
  - [en](https://longbridge.com/en/quote/603014.SH/topics.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/603014.SH/topics.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/603014.SH/topics.md)
---

# Weigao Blood Purification (603014.SH) — Community Discussions

### [The overlooked vertical niche: Blood purification shows considerable growth, Ruijian Medical's IPO unveils prospects](https://longbridge.com/en/topics/30972394.md)

- Author: [真灼财经](https://longbridge.com/en/profiles/1067948.md)
- Datetime: 2025-06-23T00:39:40.000Z
- Comments: 0
- Healthcare investment has become a hot topic this year, but most attention is focused on familiar areas like innovative drugs. From an investment opportunity perspective, highly specialized niche sect

## References

- [Weigao Blood Purification (603014.SH)](https://longbridge.com/en/quote/603014.SH.md)


> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/603014.SH/topics.md) | [繁體中文](https://longbridge.com/zh-HK/quote/603014.SH/topics.md)